anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Epizootic haemorrhagic disease (EHD), caused by the EHD virus (EHDV), is a vector-borne viral disease transmitted through Culicoides biting midges. EHDV comprises seven serotypes (1, 2, and 4-8), with EHDV-8 having recently emerged and spread in Europe over the last two years. Such event has raised concerns about the significant threat posed by EHDV-8 to livestock industry. In this study, an inactivated vaccine against EHDV-8 (vEHDV8-IZSAM) was developed. Safety and efficacy of the vaccine were evaluated in calves through clinical, serological, and virological monitoring following experimental challenge. The vaccine was proven safe, with only transient fever and localized reactions observed in a few animals, consistent with adjuvanted vaccine side effects. vEHDV8-IZSAM elicited a robust humoral response, as evidenced by the presence of neutralizing antibodies. After challenge with a virulent isolate, viraemia and clinical signs were evidenced in control animals but in none of the vaccinated animals. This study highlights the potential of vEHDV8-IZSAM as a safe and highly effective vaccine against EHDV-8 in cattle. It offers protection from clinical disease and effectively prevents viraemia. With the recent spread of EHDV-8 in European livestock, the use of an inactivated vaccine could be key in protecting animals from clinical disease and thus to mitigate the economic impact of the disease. Further investigations are warranted to assess the duration of the induced immunity and the applicability of this vaccine in real-world settings. Accordingly, joint efforts between public veterinary institutions and pharmaceutical companies are recommended to scale up vaccine production.
Participants in the mHealth delivered exercise program have up to 10 in-person visits with a physical therapist over 12 months. The mHealth exercise program, consisting of walking, strengthening and stretching exercises, is prescribed and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week. The exercise program is video-recorded and accessed on a smartphone or computer tablet via an application ("app"). Cognitive-behavioral elements are integrated emphasizing participant engagement in managing their health condition. Components of the mHealth program include goal setting, action planning, automated rewards, self-monitoring of progress and a remote connection to a physical therapist through a messaging feature.
Apparatus and associated methods relate to providing secure gatekeeping of communication from a remote internet-based website having an Internet-Protocol (IP) address to an implantable biomedical device. A gatekeeping device receives the communication transmitted by the remote internet-based website. The communication received is encoded using a first encoding algorithm. The gatekeeping device decodes the communication received. The gatekeeping device then encodes the communication decoded using a second encoding algorithm. The gatekeeping device wirelessly relays the communication encoded using the second encoding algorithm to the implantable biomedical device. In some embodiments, the gatekeeping device compares the IP address of the communication transmitted by the remote internet-based website with a predetermined static IP address corresponding to the implantable biomedical device and rejects the communication transmitted by the remote internet-based website if the IP address is not that of the predetermined static IP address corresponding to the implantable biomedical device.
The design is a prospective, multicenter, non-interventional, observational study for patients with RA who are newly prescribed eligible medications at the time of enrollment into the registry. The drug is prescribed per the physician's decision which precedes the decision to enroll the patient into the registry. Longitudinal follow-up data is obtained via CorEvitas Questionnaires completed by both patients and their treating rheumatologists during routine clinical practice. The Enrollment and Follow-Up Questionnaires capture data on patient demographics, targeted medical history including a history of all prior treatments for RA, smoking history, disease duration, disease severity, disease activity, laboratory results, comorbidities, hospitalizations and other targeted safety events.

The study will also monitor a range of clinical effectiveness, patient reported outcomes (PROs), health economic, and safety outcomes, including infections, malignancies and cardiovascular events, among other safety outcomes. Standard components of the European League Against Rheumatism (EULAR) (Disease Activity Score -28 joint count) and American College of Rheumatology (ACR) response criteria, including tender and swollen 28 joint counts, physician and patient global assessment, morning stiffness and pain will be collected at all study visits to enable comparisons of composite disease activity scores (e.g. remission) and response criteria. disease activity score (DAS)-28 erythrocyte sedimentation rates (ESR) will be calculated where possible, as Japanese physicians routinely collect ESR on a more regular basis than U.S. physicians. Composite indices of disease activity, clinical disease activity index (CDAI), DAS, and ACR scores may be calculated from the elements in the CorEvitas Questionnaire for publication. In addition, PROs will be collected via instruments including the EuroQol (EQ)-5D, health assessment questionnaire (HAQ)-DI, and work productivity activity impairment instrument (WPAI) questionnaire.

A primary objective of the registry is analysis of comparative safety. The registry may be linked to other registries for the purposes including comparative safety or outcome studies. The program-specific subject identifier number (ID) will be collected for subjects that participate or have participated in a post-market surveillance study. The ID will be used for to ensure the accuracy of safety reporting to regulators by reducing duplicate reports Note that this study has not been submitted to a United States institutional review board. It has been approved by Japanese Authorities.
BACKGROUND: Various cutoffs have been used to diagnose computed tomography (CT)-defined low skeletal muscle mass; however, the impact of this variability on predicting physical functional limitations (PFL) remains unclear. In the present study we aimed to evaluate the diagnostic test metrics for predicting PFLs using a fixed cutoff value from previous reports and sought to create a prediction score that incorporated the skeletal muscle index (SMI) and other clinical factors.
METHODS: In this cross-sectional study including 237 patients with lung cancer, the SMI was assessed using CT-determined skeletal muscle area at the third lumbar vertebra. Physical function was assessed using the short physical performance battery (SPPB) test, with PFL defined as an SPPB score ≤9. We analyzed the diagnostic metrics of the five previous cutoffs for CT-defined low skeletal muscle mass in predicting PFL.
RESULTS: The mean age of participants was 66.0 ± 10.4 years. Out of 237 patients, 158 (66.7%) had PFLs. A significant difference was observed in SMI between individuals with and without PFLs (35.7 cm2/m2 ± 7.8 vs. 39.5 cm2/m2 ± 8.4, p < 0.001). Diagnostic metrics of previous cutoffs in predicting PFL showed suboptimal sensitivity (63.29%-91.77%), specificity (11.39%-50.63%), and area under the receiver operating characteristic curve (AUC) values (0.516-0.592). Age and the SMI were significant predictors of PFL; therefore, a score for predicting PFL (age - SMI + 21) was constructed, which achieved an AUC value of 0.748.
CONCLUSION: Fixed cutoffs for CT-defined low skeletal muscle mass may inadequately predict PFLs, potentially overlooking declining physical functions in patients with lung cancer.
Synthetic peptides designated 'synthetic inducible biological response amplifiers' (SIBRA's) are new.  SIBRA is described as consisting of: a ligand binding domain, e.g. in the form of a complementary peptide; a DNA-binding region, e.g. of the zinc finger type; a trans-activating segment; and further short sequences for incorporating the SIBRA in the required cell compartment. The short sequences are e.g. an internalisation or fusion peptide sequence for locating the SIBRA from the extracellular medium into the cytosol of the cell and/or a nuclear localisation sequence of the bipartite type for incorporating the SIBRA in the cell nucleus. These domains sensitise comparable domains in cellular proteins, which are cleaved to an SIBRA and further modified to a molecule which is active in vivo and intracellularly.
Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., SNPs) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the CIMBA Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.
PROBLEM TO BE SOLVED: To obtain a Newcastle disease virus(NDV) mutant which is phenotypicaly V protein positive, in which a prescribed amount or less of its P-gene derived from mRNAs in infected cells encode V ORF, and which is useful for a live vaccine to protect birds against NDV and so on. SOLUTION: A Newcastle disease virus(NDV) mutant expresses its V protein at a reduced level (NDV V). The mutant is phenotypically V protein positive, and <=6%, preferably <=3%, more preferably 1%, of its P-gene derived from mRNAs in infected cell encode V ORF. The phosphoprotein (P) gene mRNA editing locus UUU UUC CC (genome RNA sense) comprises a mutation to reduce editing. The mutation in the editin locus is a nucleotide substitution. A live vaccine against Newcastle disease in birds comprises the NDV mutant and a pharmaceutically acceptable carrier.
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is one of the most frequently expressed angiogenic factors in tumors. Development of VEGF antagonists has become an important approach in cancer therapy. The present invention relates to an anti-VEGF strategy wherein VEGF secretion from tumors cells is prevented. The placenta growth factor-1 (PLGF-1), a member of the VEGF family lacking detectable angiogenic activity, preferentially forms intracellular heterodimers with VEGF in cells co-expressing both factors. A retroviral vector was constructed containing human PLGF-l (SEQ ID NO: 1) or VEGF with a C-terminal KDEL (SEQ ID NO: 7) sequence, which is a signal for endoplasmic reticulum (ER)-retention in mammalian cells. Transduction of murine Lewis lung carcinoma (LLC) cells with the PLGF-1-KDEL retroviral vector almost completely abrogated tumor growth and induced tumor dormancy. Consistent with the dramatic anti-tumor effect, most mouse VEGF molecules remain as intracellular VEGF/PLGF-l heterodimers and only a negligible amount of VEGF homodimers are secreted. As a result, in PLGF-1-KDEL (SEQ ID NO: 3) tumors blood vessels remain at very low numbers and lack branching and capillary networks. Gene transfer of a VEGF-KDEL construct into tumor cells likewise produced a dramatic antitumor effect. Thus, the present invention provides compositions and methods for inhibiting secretion of VEGF from cells.
This study will assess the efficacy of an emotion regulation skills-training intervention (Online EmReg) provided online to individuals with TBI with emotion regulation difficulties. Specifically, this study seeks to accomplish three aims: 1) Evaluate the efficacy of the Online EmReg intervention immediately post-intervention and at a 12-week follow-up assessment; 2) Identify factors that optimize the effectiveness of the Online EmReg intervention; 3) Explore the impact of Online EmReg on positive and negative affect, life satisfaction, and executive functioning. The study design is a randomized control trial with a waitlist control group whereby the participants in the control group undergo the training after a 12 week waiting period. 104 subjects with TBI and self-reported deficits in emotion regulation will be enrolled.

The intervention protocol calls for 24, 60-minute emotion regulation sessions twice a week for 12 weeks, delivered online via Zoom by post-doctoral level therapists with specialty training in rehabilitation neuropsychology. Study participation will last approximately 28 weeks for participants in the immediate intervention arm (4 weeks preparation, 12 weeks intervention, 12 weeks follow-up) and 40 weeks for participants in the waitlist arm (4 weeks preparation, 12 weeks waitlist, 12 weeks intervention, and 12 weeks follow-up). Core assessments will be conducted at each major time point: T1 (baseline), T2 (immediate intervention end/waitlist baseline), T3 (immediate intervention follow-up/end of waitlist intervention), and T4 (waitlist follow-up). A subset of the measures will be administered every 4 weeks between each major time point for the duration of the study.
Iobenguane is indicated as a radioactive isotope diagnosing for adrenomedullary disorders and neuroendocrine tumors.

Tumors, adrenal medulla (diagnosis): I-123 MIBG is used for diagnostic imaging of the adrenal medulla, for the evaluation and localization of intra- and extra-adrenal pheochromocytomas, paragangliomas, and neuroblastomas, as well as for localization of metastatic lesions from these tumors. I-123 MIBG can also be used for confirmation of diagnosis of pheochromocytoma when catecholamine determination tests are unclear.

Tumors, carcinoid (diagnosis): I-123 MIBG scintigraphy is used as screening procedures for suspected carcinoid tumors, especially those of intestinal origin.

Hyperplasia, adrenal medulla (diagnosis): I-123 MIBG is used in the evaluation of the adrenal medulla for disorders such as medullary hyperplasia in patients at risk of developing medullary disease (e.g., multiple endocrine neoplasia [MEN type 2, MEN type 3]).

Carcinoma, thyroid (diagnosis): I-123 MIBG is used for diagnostic imaging of medullary thyroid carcinoma.

DISTRIBUTION

After intravenous administration, there is rapid uptake of MIBG mainly in the liver, and in lesser amounts in the lungs, heart, and salivary glands. A limited number of patients may show activity in normal adrenals, lung, skeletal, muscle, and blocked thyroid glands. Although the uptake in normal adrenal glands is very low, hyperplastic adrenals and tumors such as pheochromocytoma, neuroblastoma, and other tumors with neurosecretory granules have a relatively higher uptake. Significant clearance of I-123 MIBG from the liver and the spleen occurs within 72 hours. I-123 MIBG—In adrenal medullary tumors: Initial images may be obtained 2 to 3 hours after injection. Images may also be obtained at 18 to 24 hours, and as late as 48 hours post injection. Most pheochromocytomas are visualized at 24 hours. However, due to the short half-life of I-123 MIBG, images may not be possible at times when background (e.g., liver) activity is low and imaging would be optimal. Small amounts of radioactivity used in diagnosis; radiation received is low and considered safe.

ELIMINATION

Renal; about 40 to 50% of the injected activity is eliminated within 24 hours and about 70 to 90% within 4 days (mainly as unchanged drug with small amounts of I-123 m-iodohippuric acid [I-123 MIHA], I-123 iodide, and I-123 m-iodobenzoic acid [I-123 MIBA]).
PROBLEM TO BE SOLVED: To obtain the subject preparation having high safety even in using various agents, excellent in use feeling and giving a stable emulsified material without adding a surfactant or a diluent by including an acrylic acid.alkyl methacrylate copolymer, etc., as an active component. SOLUTION: This local treating preparation contains (A) an acrylic acid.(a 10-30C) alkyl methacrylate copolymer or its salt, (B) a medical agent and (C) water as essential components. Preferably, the component A is a copolymer of a hydrophilic acrylic acid with lipophilic 10-30C alkyl methacrylate or a salt obtained by neutralizing it with a suitable basic substance and its copolymerizing ratio is >=80 pts.wt. of acrylic acid and <=20 pts.-wt. of alkyl methacrylate, and a concentration of the component A in the objective formulation is 0.1-20.0 wt.%.
Emphysematous pyelonephritis (EPN) is a necrotizing bacterial infection characterized by gas retention and a poor prognosis. We present the case of a 75-year-old man who was diagnosed early with EPN and received multidisciplinary treatment. He had poorly controlled type 2 diabetes mellitus (DM) and chronic kidney disease (CKD), and was treated with oral hypoglycemic drugs, including a sodium-glucose co-transporter-2 inhibitor. He experienced the onset of back pain in the midsection of his back, tenderness in the costovertebral angle, and a high fever (> 39 °C), accompanied by tachycardia, hypotension, and tachypnea. The patient was diagnosed with pyelonephritis and septic shock. Immediate measures encompassing empirical antibiotic therapy, administration of noradrenaline, blood glucose regulation, and urethral catheterization were implemented. However, due to the persistent fever (> 38 °C) and lack of improvement in his condition, abdominal computed tomography (CT) was repeated on the fourth day. This revealed the presence of gas around the right kidney parenchyma, leading to a diagnosis of EPN that had evolved from acute pyelonephritis. Subsequently, percutaneous drainage of the right kidney parenchyma was performed. Subsequently, multidisciplinary treatment was continued, and his condition gradually improved. Clinicians should evaluate abdominal CT when acute pyelonephritis does not improve within a few days of antibiotic therapy. Disease progression from acute pyelonephritis to EPN should be considered in patients with DM and CKD.
A dye remover composition which removes a dye based on the reductional action of a reducing agent. When applied to the scalp, the composition is less irritative to the scalp and can prevent air oxidation after a dye removal treatment. The dye remover composition is used for removing the dye from fibers dyed with an oxidation dye containing an aminated dye intermediate. It contains a reducing agent and removes the dye from the fibers based on the reductional action of the reducing agent. This dye remover composition further contains a reducing sugar. Examples of the reducing sugar include xylose and dihydroxyacetone.
INTRODUCTION: Over the last decades, arthroscopic surgery has become increasingly relevant as its minimally invasive approach offers many benefits. To investigate the risks of orthoscopic surgery at the elbow, this study aimed to investigate the development of temperatures in elbow joints while performing radiofrequency ablation in arthroscopic surgery.
MATERIALS AND METHODS: We performed standard arthroscopic surgeries with posterolateral, transtricipital and anterolateral approaches on seven cadaveric elbows and performed ablation on predefined locations with or without irrigation. Two temperature probes were positioned into the olecranon fossa and between the ulnar nerve and the medial joint capsule. The temperature data were recorded using a real-time data logger. A bipolar radiofrequency ablation (bRFA) device was used at the medial and lateral recess and in the fossa olecrani over a defined period. Data was then analyzed using Matlab.
RESULTS: Using bRFA without irrigation results in rapidly increasing temperature within the joint. A significant temperature increase was found within only 5 s without irrigation (p = 0.0052) in the fossa olecrani. We did not observe critical temperatures above 41 °C close to the ulnar nerve within 30 s under constant irrigation (p = 0.0747).
CONCLUSIONS: Radiofrequency ablation (RFA) can be safely used in elbow arthroscopy with irrigation. The continuous use without irrigation should be limited to 3 s. Despite the anatomical proximity of the ulnar nerve and capsule, we were able to show that a possible rise in temperature most likely does not affect the ulnar nerve.
A system and apparatus implementing a graphical user interface for displaying labour related information is provided. The graphical user interface displays, a first viewing window selected from a set of possible viewing windows, each viewing window in the set of possible viewing windows conveying a feature measurement related to labour progression. At least one viewing window in the set of possible viewing windows conveys a given feature measurement and a safety limit associated to the given feature measurement. The graphical user interface also displays at least one control allowing a user to select a subset of viewing windows from the set of possible viewing windows, the subset of viewing windows including at least one viewing window other than the first viewing window. The graphical user interface also displays the selected subset of viewing windows simultaneously with the first viewing window. In response to the given feature measurement exceeding the associated safety limit, the graphical user interface displays information to attract the attention of the user to the viewing window conveying the given feature measurement. As a variant, the set of possible viewing windows including one or more groupings including at least two viewing windows allowing a user to selected multiple viewing windows simultaneously. In another variant, a signal conveying a user identifier associated to a user of the system is received. At least one additional viewing window other than the first viewing window is selected for display from the set of possible viewing windows at least in part on the basis of the user identifier.
The present invention describes a beam module and a joint module for configuring a Robotic Manipulator. Opposite ends of the beam module or joint module are equipped with a male flange connection and matching a female flange connection. The matching male flange and female flange connections allow the beam module and the joint module to be configured or reconfigured in any numbers or combinations. In addition, ports of a pattern are formed on both the male flange connection and female flange connection allow reconfiguration of the Robotic Manipulator. The Robotic Manipulator may be mounted on motorised base. Fluid power is supplied through the ports. By sending commands to the motorised base and controlling the fluid power, the Robotic Manipulator is programmed to execute a trajectory and perform a repetitive task or playback the trajectory.
Adjustment of humidified high flow air therapy: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of \> 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.